Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02110121 · ClinicalTrials.gov registry record · NA
Picosure Alexandrite Laser and Revlite Nd:Yag Laser for the Treatment of Unwanted Tattoos
A NA study of Unwanted Tattoos, sponsored by Cynosure.
- Completed
- Registry status
- NA
- Development phase
- 63
- Enrollment target
- 1
- Study location
NCT02110121: Completed NA study of Unwanted Tattoos, sponsored by Cynosure.
NCT02110121 is a NA study of Unwanted Tattoos that has completed, run by Cynosure. The registered enrollment target is 63 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02110121, a NA study of Unwanted Tattoos, has completed, sponsored by Cynosure.
- COMPLETED
- Registry status
- NA
- Development phase
- 63 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the Picosure and Revlite Laser Systems for the treatment of unwanted tattoos.
Primary Outcome
Clearance will be measured using a blinded photograph evaluation scale. This ranges from 0 to 3, where a score of 0 is 0-25%, 1 is 25-50% clearance rating, 2 is 50-75%, and 3 is \>75%. Photographs will be taken of the subjects at baseline and post treatment. The results will be compared to determine clearance.
Conditions Studied
Interventions
- DEVICE Picosure Laser System
- DEVICE Revlite Laser System
Study Locations (1)
Massachusetts
- Cynosure Inc. - Westford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2014-02 |
| Est. Completion | 2017-03 |
| Phase | NA |
What the finished NCT02110121 record still lists
NCT02110121 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 63 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Unwanted Tattoos appearing as the primary indexed condition, and to 2 interventions - of which Picosure Laser System is the first listed.
NCT02110121 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT02110121 about?
NCT02110121 is a clinical study titled "Picosure Alexandrite Laser and Revlite Nd:Yag Laser for the Treatment of Unwanted Tattoos". The purpose of this study is to evaluate the Picosure and Revlite Laser Systems for the treatment of unwanted tattoos.
What is the current status of trial NCT02110121?
This trial is currently completed. It is a NA study. The enrollment target is 63 participants. The study started on 2014-02. Estimated completion is 2017-03.
What conditions does trial NCT02110121 study?
This clinical trial studies the following conditions: Unwanted Tattoos.
What interventions are being tested in trial NCT02110121?
The interventions under investigation include: Picosure Laser System (DEVICE), Revlite Laser System (DEVICE).
Who is sponsoring clinical trial NCT02110121?
This trial is sponsored by Cynosure, which has 49 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02110121 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Unwanted Tattoos
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02110121's enrollment target sits among peer trials
63 1157th of 2000 higher than 844 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03383575 · 63 participants · Phase 2
Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
- NCT04870944 · 63 participants · Phase 1
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
- NCT05031897 · 63 participants · Phase 2
Two Step Haplo With Radiation Conditioning
- NCT05312671 · 63 participants · Phase 2
Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia